Neuphoria Therapeutics Inc. last reported quarterly results on May 20, 2025, for Q3 FY2025 (the quarter ended Mar 31, 2025): revenue of $15.0 million and diluted EPS of $6.55. It usually reports 50 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 50 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
May 20, 2025
50 days after quarter end
|
Q3 FY2025
ended Mar 31, 2025
|
15
|
11
|
6.55
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NEUP (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Burlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1191070
- Former names
- BIONOMICS LIMITED/FI (until Dec 23, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.